Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Spear Bio
Spear Bio

Spear Bio

Seed

Spear Bio: Empowering patients and researchers with ultra-sensitive protein assays.

HQ
Boston, MA, US
Founded
2021
Overview
Compare
Employees

Founded with the mission to revolutionize early-stage disease diagnostics and monitoring, Spear Bio focuses on developing ultra-sensitive protein assays. The company aims to empower patients, researchers, and clinicians by enabling the detection of trace biomarkers in microsamples at scale. Their core product offerings include robust immunoassays designed for tiny sample volumes, which facilitate more precise and early detection of diseases.

Spear Bio has garnered attention for its innovative approach to protein assays, attracting notable investors and industry experts. The company's advanced technology has led to significant achievements in the field of diagnostics, enhancing the ability to monitor diseases at their earliest stages. Overall, Spear Bio's impact lies in its potential to transform how diseases are detected and managed, ultimately improving patient outcomes and advancing medical research.

Spear Bio - Similar Companies

Aperture Bio logo

Aperture Bio

aperture.bio

Accelevir Diagnostics logo

Accelevir Diagnostics

Syncell logo

Syncell

syncell.com

Amplified Sciences logo

Amplified Sciences

NanoMosaic logo

NanoMosaic

eGlint logo

eGlint

Probius logo

Probius

probius.bio

Key Proteo logo

Key Proteo

keyproteo.com

Manifold Bio logo

Manifold Bio

manifold.bio

Correlia Biosystems logo

Correlia Biosystems

correliabio.com

Signatur Biosciences logo

Signatur Biosciences

signatur.bio

Innovative Biosensors logo

Innovative Biosensors

Enable Biosciences logo

Enable Biosciences

Persperion Diagnostics logo

Persperion Diagnostics

persperiontech.com

HI-Bio logo

HI-Bio

hibio.com

Spear Bio - Quick Facts

Who are Spear Bio's competitors?

Companies similar to Spear Bio include Aperture Bio, Accelevir Diagnostics, Syncell and Amplified Sciences.

When was Spear Bio founded?

Spear Bio was founded in 2021.

Where is Spear Bio's headquarters located?

Spear Bio's headquarters is located in Boston, MA, US.

How many employees does Spear Bio have?

Spear Bio has 16 employees as of Feb 5, 2024.

Spear Bio - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Protein Assays
Tags
  • Healthtech
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified